CLINICAL TRIALS PROFILE FOR PEDIARIX
✉ Email this page to a colleague
All Clinical Trials for PEDIARIX
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00133445 ↗ | Pentavalent DTaP-Hep B-IPV | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | 2005-12-01 | The purpose of this study is to evaluate the safety of administering a combination vaccine (DTaP-HepB-IPV; Pediarix™) to infants at birth, 2 and 6 months compared to the administration of a HepB vaccine at birth and the same combination vaccine at 2, 4, and 6 months of age. Additionally, researchers will assess the body's antibody response (proteins produced by the body's immune system that help fight infections) following each vaccine dose. The study will enroll 5 healthy newborns, ages 0-5 days. Participants will be involved in study related procedures for up to 288 days, including blood sample collection and 5 study visits. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PEDIARIX
Condition Name
Clinical Trial Locations for PEDIARIX
Trials by Country
Clinical Trial Progress for PEDIARIX
Clinical Trial Phase
Clinical Trial Sponsors for PEDIARIX
Sponsor Name